- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
|---|---|---|---|---|
| 07.06. | Verve Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | |
| 31.05. | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 117 | GlobeNewswire (Europe) | |
| 31.05. | Verve Therapeutics names Lister as chief scientific officer | 1 | Seeking Alpha | |
| 31.05. | Verve Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | |
| 31.05. | Verve Therapeutics Announces Leadership Update | 85 | GlobeNewswire (Europe) | |
| 30.05. | Verve Therapeutics to Participate in Upcoming Investor Conferences | 2 | GlobeNewswire (USA) | |
| 16.05. | Verve Therapeutics gains as COO buys shares | 6 | Seeking Alpha | |
| 16.05. | MGNI, VERV and GWAV among pre-market gainers | 19 | Seeking Alpha | |
| 08.05. | Verve Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | |
| 08.05. | Verve Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | |
| 07.05. | Verve Therapeutics moves forward with backup base editing therapy | 1 | BioPharma Dive | |
| 03.05. | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 157 | GlobeNewswire (Europe) | |
| 06.04. | After a Serious Setback, Is Verve Therapeutics a Buy? | 24 | The Motley Fool | |
| 04.04. | Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More | 3 | Zacks | |
| 03.04. | Verve Therapeutics (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls | 6 | Zacks | |
| 02.04. | Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol | 16 | Benzinga.com | |
| 02.04. | Verve Therapeutics To Halt Enrollment In Heart-1 Phase 1b Trial Of VERVE-101; Stock Falls | 5 | RTTNews | |
| 02.04. | US STOCKS PVH, Verve Therapeutics, Canoo | 6 | Reuters | |
| 02.04. | Verve Therapeutics falls after it pauses enrollment in gene editing therapy study | 10 | Reuters | |
| 02.04. | Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels | 4 | Reuters |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
VERVE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
